AS

Aspen Neuroscience

<UNKNOWN>, US · 10 known investors

aspenneuroscience.com ↗

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease. The company is a clinical-stage biotechnology firm focused on personalized neuron replacement therapies.

Founders & leadership

AB

Andrés Bratt-LealCo-Founder and Senior Vice President, Research & Development

DM

Damien McDevittPresident and Chief Executive Officer

Investors · 10

AR

ARCH Venture Partners✓ verifiedChicago · $50K – $250M

LI

Lifeforce Capital✓ verifiedChevy Chase · $500K – $5M

OR

OrbiMed✓ verifiedNew York · $1M – $75M

DO

Domain Associates✓ verifiedPrinceton · $200K – $15M

ED

EDB Investments✓ verifiedSingapore · $12M – $400M

SE

Section 32✓ verifiedPalo Alto

FR

Frazier Life SciencesPalo Alto

GV

GV (Google Ventures)Mountain View · $250K – $50M

ME

Medical Excellence CapitalNew York

S3

S32reportedPalo Alto